Mainz Biomed (NASDAQ:MYNZ – Free Report) had its target price reduced by HC Wainwright from $9.00 to $5.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2023 earnings at ($0.31) EPS, FY2023 earnings at ($1.67) […]
Related Keywords
Mainz Biomed , Nasdaq , Cantor Fitzgerald , Free Report , Biomed Trading Down , Get Free Report , Mainz Biomed Daily , Nasdaq Mynz , Mynz , Medical , Lower Price Target , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.